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□  Malaria 101: Early history, biology, and epidemiology
□  The first push for malaria eradication (1950-1970)
□  Worsening of malaria control (1990s)
□  New focus and scale-up success (2000-2010)
> Is eradication possible now?
History: Major Scientific Milestones
Charles Alphonse Laveran Ronald Ross Giovanni Batista Grassi
Demonstrated parasites Discovered Anopheles Demonstrated life cycle from 
in patient's blood, 1880 mosquito as vector, 1897 mosquito to man, 1898-1899
Malaria Biology: The Human Malaria Parasites
Intra-erythrocytic protozoan „ *
Human m alaria: 4 m ajor species v '* _
> P l a s m o d i u m  f a l c i p a r u m
>  P l a s m o d i u m  v i v a x  y  J
>  P l a s m o d i u m  o v a l e
>  P l a s m o d i u m  m a l a r i a e
□  P .  f a l c i p a r u m
>  Potentially fatal severe disease
■ Red blood cell destruction ^severe anemia
■ Sequestration in cerebral vessels ^coma
> Multi-drug resistant
Malaria Biology: Vectors of Human Malaria
□  >400 species of Anopheles mosquitoes found 
worldwide; ~50 transmit malaria
□  Each species occupies distinct ecological niche
□  Major African vectors tend to bite indoors and at night
□  Biting and resting behavior affect transmission 
potential and control





~250 million clinical cases per year; 80% in Africa
> Children aged <5 years and pregnant women most affected
>800,000 deaths per year; >90% in Africa 
Disability from severe forms of the disease 
Annual economic burden
> GDP ^1.3% loss
Prevalence of P .  f a l c i p a r u m  Malaria in 
Children Aged 2 - 1 0  Years
Events Leading up to 
the Global Malaria Eradication Program
□  Early successes in mosquito control (Panama Canal)
□  Effective interventions, chloroquine and DDT, became 
available after WWII
□  Availability of good diagnosis with microscopy




Eradication Strategies 1 9 5 0 - 1 9 7 0
□  “Magic bullet” : DDT indoor residual 
spray (IRS)
□  A ssum ptions
> People stay indoors at night
> A n o p h e l e s  mosquito bites at night, rests indoors 
on house walls, and receives a toxic dose of DDT
□  O ther m ajor activities
> Antimalarial drug treatment: Patients, occasionally 
as mass treatment






Malaria was eliminated in 37 countries during 1950-1978
1950 1978
What Were the Problems?
Technical Insecticide and drug resistance
Logistics Supply chain failures 
Poor delivery of IRS
Strategic Rigidity
Lack of research 
Africa not included
Financial Funds diverted elsewhere
Sociocultural Lack of community buy-in and participation 
Decreasing acceptance of IRS
IRS, Indoor residual spraying
Consequent Change in Strategy (1 9 7 0 s)
□  22nd World Health Assembly (1969)
> “Suspended” eradication campaign
> Goal became control to “Minimize the health damage by malaria”
■ Less ambitious
■ Strategy adapted to local context
□  Shift from prevention with insecticides/DDT to 
antimalarial treatment
□  Integrate activities into primary health care
DDT, Dichlorodiphenyltrichloroethane
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Worsening of Malaria Control (1 9 9 0 s)
□  Decreased funding
□  Intensification and spread of chloroquine resistance







political leadership in endemic countries 
tools (drugs, bed nets)
A  C O M M IT M E N T  TO  M A L A R IA  C O N T R O L
A N D  P R E V E N T IO N :
T H E  F IR S T  S T E P S  T O W A R D S  EL IM IN A T IO N
John R. MacArthur, MD, MPH
C h i e f ,  P r o g r a m  I m p l e m e n t a t i o n  U n i t  
Division of Parasitic Diseases and Malaria 
Center for Global Health 
Centers for Disease Control and Prevention
□  Roll Back Malaria and
U.N. Millennium Development Goals
□  President’s Malaria Initiative (PMI)
> PMI under two presidents
> Goals, targets, and funding
> Focused interventions
> CDC’s role in PMI: Strategic information
□  Results achieved
> Significant reductions in malaria transmission
Roll Back Malaria (RBM)
□  Global partnership
> Launched in 1998
> WHO, UNICEF, UNDP, World Bank
□  Global framework
> Coordination of activities
> Mobilization of resources
> Establishment of technical working groups
> Establishment of subregional networks
□  Global Malaria Action Plan
> Launched September 25, 2008, by RBM partnership
> Scaling up for impact
> Sustaining control over time
www.rollbackmalaria.org
UNICEF, United Nations Children’s Fund
UNDP, United Nations Development Program
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United Nations Millennium Development Goals (MDG)
www.un.org/millenniumgoals
□  Goal 4: Reduce child mortality
□  Goal 5: Improve maternal health
□  Goal 6: Combat HIV/AIDS, malaria, and other diseases
> Target 6c: Have halted by 2015 and begun to reverse the incidence 
of malaria and other major diseases
Incidence and death rates associated with malaria 
Children under 5 sleeping under insecticide-treated bednets 





A Galeway to the UN System’s Work on the MDGs
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International Financial Disbursements 
to Malaria Endemic
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PMI, President’s Malaria Initiative .
19 GF, Global Fund
President’s Malaria Initiative (PMI)
□  On June 30, 2005, President Bush announced a new 
initiative to rapidly scale up malaria control 
interventions in high-burden countries in Africa
> 5-year and $1.2B investment
□  Challenged other donors to increase their funding
□  PMI is led by USAID and 
co-implemented with CDC
PMI Goal and Targets
□  Goal: Reduce malaria-related mortality by 50% 
in 15 selected countries
□  Targets: Achieve 85% coverage of vulnerable groups 











treatment in pregnancy (IPTp)
PMI Funding Levels and Coverage
Year Funding Level No. Countries Covered
2006 $30 M 3
2007 $135 M 7
2008 $300 M 15
2009 $300 M 15
2010 $500 M 15
TOTAL $1,265 M
PMI and the Global Health Initiative (GHI)
□  President Obama signals support for global health 
including malaria (September 2008)
□  The White House launches Global Health Initiative
> U.S. Government will invest $63 billion over 6 years
□  PMI is now a major component of GHI
I"We will not be successful in our efforts to end deaths from 
AIDS, malaria, and tuberculosis unless we do more to improve 
health systems around the world, focus our efforts on child and 
maternal health, and ensure that best practices drive the 
funding for these programs.“
—President Barack Obama, May 5, 2009
CDC’s Mandate in PMI 
Strategic Information
□  U.S. Congress (through the Lantos-Hyde Act, 2008) 
charged CDC to take a leading role in strategic 
information
> Monitoring and evaluation
> Surveillance
> Operations research
a n  act
To authorize appropriations for fiscal years 2009 through 2013 to provide assistance to foreign countries to combat HIV/AIDS, tuberculosis, and malaria, and for other purposes.
Be it enacted by the Senate and House of Representatives of 
the United States of America in Congress assembled,
SECTION 1. SHORT TITLE; TABLE OF CONTENTS.
(a) Short Title.— This Act may be cited as the “Tom Lantos 
and Henry J. Hyde United States Global Leadership Against HIV/ 
AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008”.
□ CDC is advising the U.S. Malaria Coordinator on priorities 
for these activities and being a key implementer
http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbnam e=110_cong_bills&docid=f:h5501enr.pdf
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PMI Focus: Additional African Countries
Nigeria and 
the Democratic Republic of Congo 
account for the 23% 
of the world’s burden 
of the falciparum malaria
Proportion of Households with at Least 1  Insecticide- 
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Proportion of Children Aged < 5  Years Who Slept 
Under an ITN the Previous Night
_  P r e - P M I  S u r v e y s  (2003-2006) ■  Post-PMI S u r v e y s  (2007-2010)

























Zanzibar: Intervention Coverage and 
Malaria control
2003 2004 2005 2006 2007
ijn S \ / \  i R s  A C T  Malaria positivity rate
ITN, Insecticide-treated bed net
IRS, Indoor residual spraying





























Declines in All-Cause Mortality in Children Aged 
< 5  Years, 7  PMI Countries, 2 0 0 3 - 2 0 1 0




Data source: Dem ographic Health Survey, http://www.measuredhs.coom
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Resistance -  A Lurking Threat
□
□
Emergence of insecticide resistance in Africa
> DDT, pyrethroids
Emergence of artemisinin resistance in Southeast Asia
> Thai-Cambodia border
988; No. of Pages 8 ARTICLE IN PRESS
Cel
r n L I s
Pyrethroid resistance in African 
anopheline mosquitoes: what are the 
implications for malaria control?
Hilary Ranson1, Raphael N'Guessan2'5, Jonathan Lines3, Nicolas Moiroux4,5, 
Zinga Nkuni3 and Vincent Corbel4,5
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□  Massive scale-up of control interventions has been 
followed by substantial decreases in all-cause mortality 
in children aged <5 years
□  Initiative-wide impact assessment is under way
C D C ’s S C IE N T IF IC  E V ID E N C E  B A S E  F O R  S C A L E -U P  
A N D  P O S IT IO N IN G  F O R  M A L A R IA  E L IM IN A T IO N
S. Patrick Kachur, MD, MPH
C h i e f ,  S t r a t e g i c  a n d  A p p l i e d  S c i e n c e s  U n i t  
Division of Parasitic Diseases and Malaria 
Center for Global Health 
Centers for Disease Control and Prevention
Overview
1. Scientific evidence: Basis for current interventions
2. Global Malaria Eradication Research Agenda
3. CDC operational research priorities, 2010
1. Scientific Evidence: 





Indoor residual spraying 
(IRS) (where appropriate)
Intermittent preventive 
treatment in pregnancy (IPTp)
Efficacy of ITNs on All-Cause Child Mortality 
from 4 Randomized Controlled Trials in Africa









IV, Fixed, 95% Cl
1 Controls with no nets
11596 11439 -0.3425 (0.157) 0.71 [0 .5 2 ,0 .9 7 ]Kenya (Nevill)
Ghana (Binka) 18457 18054 -0.1985 (0.093) — ■— 0.82 [ 0.68, 0.98 ]
Burkina Faso (Habluetzel) 14773 14118 -0.1508 (0.1139) — ■— 0.86 [0.69, 1.08]
(  Kenya (Phillips-Howard) j
S u b to ta l ( 9 5 %  C l )
17833 18099 -0.1744 (0.058) ■
♦
0.84 [ 0.75, 0.94 ]
0 .8 3  [ 0 . 7 6 , 0 . 9 0  ]
k _____________________ __________________________  _______  ______________  __________
17% protective efficacy against child mortality before age of 5 years 
Could save 5.5 lives for every 1,000 children protected
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ITN, Insecticide-treated bed net
C Lengeler. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database of 
Systematic Reviews 2004, Issue 2.
Additional Lessons from the KEMRI/CDC 
ITN Trial and Follow-up Studies
□  People without nets experienced the same benefit if 
they lived within 300 meters of net users -  reduction in
> Parasite infection (odds ratio=0.59)
> Malaria illness (odds ratio=0.52) ,----------------------------------- ,
CopiKh 0 3«»? N Th: Amtnai Socirtj o( Trcpical Nhkor and H\*oe
> Anemia (odds ratio=0.53) COMUNITY-WIDE EFECTS OF PERMETHRIVTREATED BED NETS ON CHILD> Child mortality (hazard ratio=0.72) MORTALITY AND MALARIA MORBIDITY IN WESTERN KENYA
KEMRI, Kenya Medical Research Institute 
ITN, Insecticide-treated bed net
Hawley et al. Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in
3 8  western Kenya. Am J Trop Med Hyg 2003;68(s4):121-7.
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Afisrrart Spatial analysts of the effect of insecticide (permelhrin)-trtated bed ntls HTNs) on nearby households 
both with and without ITNs was performed in the context of a large-scale. eroup-randombed. controlled mortality trial 
in Asembo. western Kenya. Results illustrate a protective effect of ITNs on compounds lacking ITNs located within SJ) 
meters of compounds with ITNs for child mortality, moderate anemia, high-dtnsity parasitemia, and hemoglobin levels. 
This community effect on nearby compounds without nets is approximately as strong as the effect observed within 
villages with ITNs. This implies that in areas with intense malaria transmission with high ITN coverage, the primary 
effect of iitsccticidc-lrcatcd nets is via area-wide effects on the mosquito population and not. as commonly supposed, by 
simple imposition of a physical barrier protecting individuals from biting. The strength of the community effect de­
pended upon the proportion of nearby compounds with treated nets. To maximize their public health impact, high 
coveraec with treated nets is essential.
Additional Lessons from the KEMRI/CDC 
ITN Trial and Follow-up Studies
Survival benefit lasted beyond 6 years 
Mortality rates
> Infants: 113/1,000
> Children 1-5 years old: 28/1,000
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Nations Development Program, ihr 
United Nations Children's Fund, and the World Bank, aims to halve malaria mortality by 2010 through implemen­
tation ol 4 key technical strategies, in vrtkldf-treated hednetv improved case
See also Patient Page.
Context Insecticide-treated bednets reduce malaria transmission and child morbid­ity and mortality In short-term trials, but this Impact may not be sustainable. Previous investigators have suggested that bed net use might paradoxically increase mortality in older children through delayed acquisition of immunity to malaria.
Objectives To determine whether adherence to and public health benefits of Insec-1 tidde-treated bednets can be sustained over time and whether bednet use during in-1 fancy Increases all-cause mortality rates In older children In an area of Intense peren-1 nial malaria transmission.
Design and Setting A community randomized controled trial in western Kenya (phase 1: January 1997 to February 2000) followed by continued surveillance of adherence, en- tomdogic parameters, morbidity indicators, and al-cause mortality (phase 2: April 1999 to February 2002). and extended demographic monitoring (January to December 2002). I 
Participants A total of 130000 residents of 221 villages in Asembo and Gem were I randomized to receive insecticide-treated bednets at the start of phase 1 (111 vil-1 lages) or phase 2 (110 villages).
Main Outcome Measures Proportion of children younger than 5 years using in-1 secticide-treated bednets, mean number of Anop/ie/es mosquitoes per house, and all-1 cause mortality rates.
Results Adherence to bednet use in children younger than 5 yean increased from 65.9% I
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KEMRI, Kenya Medical Research Institute
ITN, Insecticide-treated bed net X X
Lindblade et al. Sustainability of reductions in malaria transmission and infant mortality in western Kenya with use _ I f f
3 9  of insecticide-treated bed nets: 4-6 years of follow-up. JAMA 2004;291(21):2571-80.
Additional Lessons from the KEMRI/ CDC 
ITN Trial and Follow-up Studies
□  Providing nets to 65% of older children and adults 
would protect even children without nets
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ITN, Insecticide-treated mosquito net
Killeen et al. Preventing childhood malaria in Africa by protecting adults from mosquitoes with insecticide-treated
40 nets. PLoS Medicine 2008;4(7):e229.
Policy Impact of the KEMRI/ CDC 
ITN Trial and Follow-up Studies
Established the evidence-base for widespread 
scale-up and universal coverage
FROM EVIDENCE TO POLICY
Continued progress in scale-up and elimination
will require improved tools 
for malaria control and surveillance
□  Scale-up: Aims to reduce morbidity and mortality
□  Elimination: Aims to reduce transmission
> Basic reproduction number <1.0
2. Global Malaria Eradication Research Agenda





□  Strategies to manage resistance to antimalarial drugs 
and insecticides for public health
> Combination treatments
> Combined delivery systems
> Rotational or mosaic deployment
Global Malaria Eradication Research Agenda
□  Alternative vector interventions
> ITNs and spraying work against mosquitoes i
> Some mosquitoes feed and rest outdoors
■ Larviciding
■ Spatial repellants, baited traps
□  Drug interventions for reducing transmission
> Mass screen and treatment
> Transmission-blocking agents
□  Surveillance: Detecting and responding to local 
transmission
3. CDC Operational Research Priorities in 2010
From Scale-up To Elimination
□  Optimize current malaria control interventions
□  Establish role for new and revisited interventions
> Research and development
> Clinical and field trials of new interventions
□  Integration with other initiatives
Research and Development: 
Field-Ready, High-Sensitivity Test for Malaria
□  WHO now calls for universal access 
to malaria diagnosis and treatment 
for every case of suspected malaria
□  Diagnostic confirmation
> Minimize the overuse of treatments
> Improves detection and treatment of 
other causes of illness
> Forms the basis of a reliable system for 
monitoring malaria and malaria control
Rapid antigen detection
Research and Development: 
Field-Ready, High-Sensitivity Test for Malaria
□  As endemic countries approach elimination, highly 
sensitive tests become more critical
□  Current diagnostic formats will improve management 
of malaria illness
□  Elimination may rest on molecular assays
> Available only in reference laboratories far from remote areas
Molecular assays
Research and Development: 
Field-Ready, High-Sensitivity Test for Malaria
□  CDC and University of Georgia
□  Novel system for molecular diagnosis
□  Real-time fluorescence loop-mediated 
amplification: Real LAMP
> Detection of malaria parasites at very low numbers
> Without access to reference laboratory staffing „ ..... ., . , 3 Real-LAMPand equipment
> Validation of the first generation prototype 
on specimens from Tanzania completed
N Lucchi, e t  al. (2010). Point of Care Diagnosis for Malaria by Fluorescence Loop-Mediated Isothermal 
Amplification. PLoS Medicine; in press.
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Clinical and Field Trials of New Interventions
□  Phase III malaria vaccine trial in Kenya
> First candidate vaccine to reach this stage of development
> One of 11 sites in 9 countries
> Could reduce clinical malaria by up to 35%, severe malaria by 49%
PL Alonso, e t  al. (2004). Efficacy of the RTS,S/AS02A vaccine against P la sm o d iu m  fa lc iparu m  infection and 
disease in young African children: randomised controlled trial. L a n c e t 364(9443):1411-20.
StS-VlCfis
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Clinical and Field Trials of New Interventions
□  When will we have a vaccine that can eliminate malaria?
> Current vaccine within 18-24 months
> Will reduce illness burden, not transmission
> Hundreds of other candidates in development
> Millennia of co-evolution confound development
Clinical and Field Trials of New Interventions
□  Combined impact of ITNs with indoor 
residual spraying
> Western Kenya (2008-2010)
> Northern Ghana (starting 2011)
□  Combined impact of ITNs with 
insecticide-treated durable wall liners
> Lakeside Malawi (starting 2011)
ITN , Insecticide-treated bed net
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Integration Opportunities
From Scale-up To Elimination
□  Community-based control/ elimination
□  Integrated case management 
interventions
□  Integrated vector control
□  Integrated surveillance, monitoring and 
evaluation
From Scale-Up to Elimination: 
the Role of Partnership
□  Creative partnerships within the U.S. government
> Within Department of Health and Human Services
> With U.S. government partners
□  Partnerships beyond our system
(¡¡g£t N a t io n a l  In s titu te s  o f  H e a lth
Turning Discovery Into Health
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